Dianthus Therapeutics (DNTH) EBIT (2017 - 2025)

Dianthus Therapeutics' EBIT history runs 9 years deep, the most recent figure standing at -$40.3 million for Q3 2025.

• In Q3 2025, EBIT fell 34.74% year-over-year to -$40.3 million; the TTM figure through Sep 2025 stood at -$140.3 million (down 69.24% YoY), while the FY2024 annual figure was -$101.9 million, down 111.45% from the prior year.
• EBIT was -$40.3 million for Q3 2025 at Dianthus Therapeutics, down from -$34.9 million in the prior quarter.
• In the past five years, EBIT ranged from a high of -$7.7 million in Q1 2023 to a low of -$40.3 million in Q3 2025.
• Historically, EBIT has averaged -$20.7 million across 5 years, with a median of -$18.2 million in 2021.
• The sharpest annual moves came in 2023 and 2024: EBIT jumped 67.76% in 2023, then sank 146.34% in 2024.
• A 5-year view of EBIT shows it stood at -$20.1 million in 2021, then soared by 46.91% to -$10.7 million in 2022, then retreated by 21.16% to -$13.0 million in 2023, then tumbled by 146.34% to -$31.9 million in 2024, then dropped by 26.23% to -$40.3 million in 2025.
• The last three EBIT figures came in at -$40.3 million (Q3 2025), -$34.9 million (Q2 2025), and -$33.2 million (Q1 2025), per Business Quant data.